Literature DB >> 1839230

Assessment of heparin anticoagulation during peripheral angioplasty.

C C Mulry1, R F Le Veen, M Sobel, P J Lampe, D R Burke.   

Abstract

The amount of heparin administered during peripheral angioplasty procedures is controversial and varies greatly among angiographers. Complications may result from both excessive and insufficient anticoagulation. The authors characterized the anticoagulant response to heparin in patients undergoing angioplasty by means of the activated clotting time (ACT). The ACT was measured in 64 patients who underwent lower extremity angioplasty. There was a linear relationship between heparin dose and ACT (P = .0001), but the slope of this relationship varied from patient to patient (R2 = .232). The response to heparin was blunted in one patient with thrombosis, but it was not exaggerated in patients with hematomas. Heparin anticoagulant response is highly variable, and heparin administration should be individualized according to ACT to produce a desired level of anticoagulation. Use of the ACT is a convenient and reproducible means of monitoring heparin administration and may increase safety and efficacy during peripheral angioplasty.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1839230     DOI: 10.1016/s1051-0443(91)72486-x

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  3 in total

1.  Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.

Authors:  Anne-Céline Martin; Sarah Lessire; Isabelle Leblanc; Anne-Sophie Dincq; Ivan Philip; Isabelle Gouin-Thibault; Anne Godier
Journal:  Clin Cardiol       Date:  2018-05-10       Impact factor: 2.882

2.  Percutaneous transluminal atherectomy of the superficial femoral and popliteal arteries: long-term results in 48 patients.

Authors:  S J Savader; A C Venbrux; S E Mitchell; S O Trerotola; M C Wang; T A Sneed; G B Tudder; M Rosenblatt; G B Lund; F A Osterman
Journal:  Cardiovasc Intervent Radiol       Date:  1994 Nov-Dec       Impact factor: 2.740

3.  Activated clotting time level with weight based heparin dosing during percutaneous coronary intervention and its determinant factors.

Authors:  Majid Soleimannejad; Naser Aslanabadi; Bahram Sohrabi; Morteza Shamshirgaran; Ahmad Separham; Babak Kazemi; Ebrahim Khayati Shal; Reza Madadi; Hamidreza Shirzadi; Hoda Azizi; Samad Ghaffari
Journal:  J Cardiovasc Thorac Res       Date:  2014-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.